Lv1
60 积分 2022-10-16 加入
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
3个月前
已完结
Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing
3个月前
已完结
Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning
3个月前
已完结
Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?
3个月前
已完结
Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates
4个月前
已完结
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial
4个月前
已完结
Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities
4个月前
已完结
Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's disease
4个月前
已完结
Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn’s Disease
4个月前
已完结
Inadequate Efficacy of Biologics for Treating Proximal Ileal Lesions in Crohn’s Disease; a prospective multicenter study
4个月前
已关闭
皖公网安备34019202002308
